MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyab083

Медицинская библиотека · The oncologist · 2022

Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer.

Tan Ruoding, Yun Cindy, Seetasith Arpamas, Sheinson Daniel, Walls Robert, Ngwa Innocent, Reddy Josina C, Zhang Qing, Secrest Matthew H, Lambert Peter, Sarsour Khaled

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Amid continued uncertainty about the management of cancer patients during the pandemic, this study sought to obtain real-world data on the use of immune checkpoint inhibitors (ICIs) before COVID-19 diagnosis and its association with severity and survival outcomes in cancer patients who contracted COVID-19.

METHODS

Cancer patients diagnosed with COVID-19 were identified from a large electronic health record database; those treated with ICIs before COVID-19+ diagnosis were matched in a 1:2 ratio to those not treated with ICIs, using a 2-step matching procedure. A descriptive analysis examined the difference in COVID-19 mortality (30-day and overall) and severity outcomes between the 2 cohorts, and overall survival was compared.

RESULTS

Among 17 545 adults ≥18 years with cancer who tested positive for COVID-19 between February 20, 2020, and January 28, 2021, in the US, 228 ICI-treated patients were matched to 456 non-ICI-treated patients, comprising the 2 study cohorts. Clinical characteristics differed significantly between the 2 cohorts before matching, with metastatic disease, lung cancer, a history of smoking, and the presence of pulmonary comorbidities being more common in the ICI-treated cohort; after matching, the 2 cohorts were similar. There were no significant differences between the ICI-treated and non-ICI-treated cohorts for 30-day mortality (12.7% vs. 14.9%, P = .235), overall mortality (22.4% vs. 22.4%, P = 1.000), hospitalization (38.6% vs. 39.0%, P = .912), or emergency department visits (16.7% vs. 14.7%, P = .500). Overall survival was similar between the 2 cohorts.

CONCLUSION

This analysis adds to the clinical evidence base that use of ICIs before SARS-CoV-2 infection does not affect COVID-19 severity or survival outcomes, supporting the continued use of ICIs in cancer patients during the pandemic.

Для цитирования: Tan Ruoding, Yun Cindy, Seetasith Arpamas, Sheinson Daniel, Walls Robert, Ngwa Innocent, Reddy Josina C, Zhang Qing, Secrest Matthew H, Lambert Peter, Sarsour Khaled. Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer.. The oncologist. 2022. DOI: 10.1093/oncolo/oyab083.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.